The skin as a metabolic and immune-competent organ: Implications for drug-induced skin rash

Amy Sharma\textsuperscript{a,1}, Yoshiro Saito\textsuperscript{b}, Shuen-Lu Hung\textsuperscript{c}, Dean Naisbitt\textsuperscript{d}, Jack Utrecht\textsuperscript{e} and Jeanine Bussiere\textsuperscript{a}\textsuperscript{,6}

\textsuperscript{a}Amgen Research, Thousand Oaks, CA, USA; \textsuperscript{b}Division of Medicinal Safety Science, National Institute of Health Sciences, Tokyo, Japan; \textsuperscript{c}Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan; \textsuperscript{d}University of Liverpool, Liverpool, UK; \textsuperscript{e}Faculty of Pharmacy and Medicine, University of Toronto, Toronto, Canada; \textsuperscript{f}Genentech Inc., South San Francisco, CA, USA

ABSTRACT

Current advances in the study of cutaneous adverse drug reactions can be attributed to the recent understanding that the skin is both a metabolically and immunologically competent organ. The ability of the skin to serve as a protective barrier with limited drug biotransformation ability, yet highly active immune function, has provided insights into its biological capability. While the immune response of the skin to drugs is vastly different from that of the liver due to evolutionary conditioning, it frequently occurs in response to various drug classes and manifests as a spectrum of hypersensitivity reactions. The skin is a common site of adverse and idiosyncratic drug reactions; drug-specific T-cells, as well as involvement of innate immune response, appear to be key mechanistic drivers in such scenarios. Association of other factors such as human leukocyte antigen (HLA) polymorphisms may play a significant role for particular drugs. This review aims to integrate emerging findings into proposed mechanisms of drug metabolism and immunity in the skin that are likely responsible for rashes and other local allergic responses. These unique biological aspects of the skin, and their translation into implications for drug development and the use of animal models, will be discussed.

Introduction

Recent advances in the knowledge of skin immunology and enzymatic ability have reshaped our understanding of the skin and its ability to respond to drugs and other foreign materials. Current evidence strongly suggests that most skin rashes are immune-mediated. In many cases, the immune response appears to be triggered by a chemically reactive drug or a reactive metabolite. Though the skin has limited ability to metabolize drugs (sulfotransferase and acetyltransferase have the greatest activity with only limited cytochrome P\textsubscript{450} activity), the immune activity is quite high. Animal models are an essential tool to test hypotheses, and have enabled an understanding of the relationship between the metabolic capability and immunology of the skin. One of the few animal models of drug-induced skin rash is due to nevirapine in rats, which will be described in this review. This model highlights many of the unique physiologic features of the skin and demonstrates what chemical species is responsible for the rash, namely a reactive sulfate metabolite formed in the skin. However, other drugs that cause skin rashes in humans do not generally cause skin rashes in animals; the dominant response appears to be immune tolerance. Therefore, it may be possible to produce other animal models of drug-induced skin rash by impairing immune tolerance.

Drugs can induce a wide variety of skin reactions. Maculopapular exanthema (MPE) and erythema multiforme (EM) are common drug-induced skin rashes. Severe cutaneous adverse reactions (SCAR) are life-threatening drug hypersensitivity reactions, carrying high mortality and morbidity. SCARs include drug-induced hypersensitivity syndrome (DIHS), drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) (Duong et al. 2017). Most reactions are likely allergic in nature, and thus hard to evaluate with animals in the non-clinical stage. The following further describes these clinically important types of skin reactions.

MPE is characterized by various erythema or papular eruptions, which are diffusely distributed on the body (Fernandez et al. 2009). Erythema is relatively homogeneous and divided into epidermal and dermal types. In the lesion, infiltration of lymphocytes is observed. MPE often occurs from 1–2 w following drug administration, and can be due to diverse drugs such as antibiotics (e.g. penicillin and sulfa drugs), antiepileptics (carbamazepine), allopurinol, or non-steroidal anti-inflammatory drugs (NSAID). This is a mild type of skin reaction and often resolves on stopping the medication.

EM is a skin disorder with a multiform of target lesions (usually three layers) with no or mild mucosal exanthema, and is due to diverse causes, including herpes simplex virus and various drugs (Lamoreux et al. 2006). EM can be divided into EM minor (in which lesions are limited to the face and four limbs) and EM major (with multiple lesions and fever). EM major leads to erythroderma by fusion of the lesions and may involve internal organ failure. EM is likely a delayed-type hypersensitivity reaction, and T-cell infiltration into the skin is often observed.

DIHS is often diagnosed by high-fever, maculopapular rash, involvement of at least one internal organ (mainly liver), blood...
abnormalities (lymphocytosis, eosinophilia, atypical lymphocytes, lymphadenopathy, and human herpesvirus six reactivation (Shiohara et al. 2006). DRESS show similar symptoms, but have different diagnostic criteria such as no viral re-activation (Lally and Turner 2007). DHIS develops from 2–6-week after drug administration, and is due to limited drugs (i.e. anti-epileptics, allopurinol, sulfa drugs, melexitine, and minocycline), and requires hospitalization, with outcomes of high mortality (10%) and increases of the chemokine TARC/CCL17 in blood.

SJS/TEN represents the most severe forms of skin reactions (Duong et al. 2017). SJS/TEN show symptoms of wide-spread blistering exanthema, high fever, and, in SJS, mucosal injury. SJS/TEN are thought to be similar disorders classified by skin detachment/blistering among areas of the epidermis: <10% of body surface area (BSA); SJS, 10%–30% of BSA; SJS/TEN overlap, and >30% of BSA:TEN. These reactions are very rare (1–5 cases/yr/1 million subjects) and develop within several days to weeks after initiating the drug. Patients suffering from SJS/TEN are hospitalized, and mortality rates are relatively high (SJS: 1–5%, TEN: 20–30%). Even after recovery, patients may suffer sequelae, such as vision loss due to pseudo-membrane formation (Duong et al. 2017).

The lymphocyte transformation test (LTT, also drug-induced lymphocyte stimulation test) is one of the clinical tests used for investigating the suspected drugs. It detects proliferation of circulating drug-specific memory T-cells, and its sensitivity is relatively high (60–70%), particularly for DHIS, and MPE, but not for TEN (Pichler and TIlch 2004). As its sensitivity is high but specificity is not, positive results mean this drug is probably causative, but negative results do not imply exclusion of the drug as the causal agent.

Immune responses of the skin to drugs

The adaptive immune response: Overview

The immune system is quite complex, and while there are similarities between immune responses in the skin and other organs, there are also differences. A major difference between the immune response in the skin versus the liver is that the dominant immune response in the liver is immune tolerance. This is illustrated by the difference in the ease of transplanting liver and skin (Calne et al. 1969). Many cells are involved in dermal immune responses, including γδ and γδ T-cells, natural killer (NK) cells, B-cells, mast cells, and macrophages (Di Meglio et al. 2011). In addition, Langerhans cells (which express langerin) are a unique antigen-presenting cell (APC) in the skin. The APC are essential for initiation of an adaptive immune response. Originally, APC were thought to be responsible for initiating most immune responses in the skin. However, as it then been found that there are other cells that express langerin, including dermal dendritic cells (DC) (Clausen and Stoitzner 2015). Such DC appear to be required for T-cell-mediated immune responses in the skin.

Co-stimulatory and co-inhibitory pathways signal simultaneously to regulate whether antigen exposure will lead to T-cell activation. Danger signals released as a result of cell stress due to direct drug toxicity are an important stimulus for the up-regulation of co-stimulatory ligands on APC (Gallucci and Matzinger 2001). Similarly, it has been shown that dysregulated co-inhibitory receptor signaling can propagate autoimmunity (Chuang et al. 2005), and that blocking these pathways (such as PD-1 and CTLA-4) in cancer models can significantly enhance functional T-cell responses (Koui et al. 2000; Hodi et al. 2010).

As discussed above, drug exposure can result in an array of cutaneous hypersensitivity reactions that vary in severity. Mild-to-moderate conditions, such as MPE, involve the preferential activation of perforin-producing CD4 T-cells, and in the case of β-lactam reactions, T-helper (Th1)-22 cells play a dominant role (Castrejon et al. 2010; Whitaker et al. 2011; Sullivan et al. 2018). In contrast, urticaria is mediated by plasma cell-generated IgE antibodies, and pustular exanthema is mediated by neutrophils (Pichler 2003).

Various SCAR develop more rapidly and severely after the first episode in recurrent patients, suggesting that the pathogenesis of SCAR involves an immune memory response. The skin lesions of SCAR show infiltration of immune cells, in which, SJS and TEN have predominately CD8 T-cells and NK cells (Nassif et al. 2004; Wei et al. 2012; Yun et al. 2013; Cho et al. 2014). CD8 T-cells (also known as cytotoxic T-cells; CTL) have been shown to produce cytokines (e.g. interleukin [IL]-15 and IL-2), chemokines, and cytotoxic proteins (e.g. granulysin and granzyme B), to induce cutaneous inflammation and kill keratinocytes in SJS/TEN (Chung et al. 2008; Su et al. 2017). With the exception of abacavir, certain drugs can activate CD4 and CD8 T-cells in all hypersensitive patients (Pichler 2003; Adam et al. 2012; Lucas et al. 2015).

Proposed mechanisms for drug-induced hypersensitivity reactions in the skin

Three models have been proposed to examine the antigenicity of small-molecule drugs (Chung et al. 2016). The first is the hapten hypothesis, which goes back many years to the work of Landsteiner and Jacobs (1935) who found that small molecules did not generally induce an immune response unless they covalently bound to proteins and thus formed an altered or “foreign” protein. However, foreign proteins do not provoke much of an immune response in the absence of activation of APC. This led to the second hypothesis, namely the danger hypothesis proposed by Matzinger (1998), which stated that unless something was causing damage and triggered an innate sense of danger, the immune system ignored it. This damage could lead to production of danger-associated molecular pattern (DAMP) molecules that activate APC. Therefore, the hapten and danger hypotheses are complementary.

The third hypothesis stems from a concept of interaction of drugs with immune receptors that do not involve a reactive metabolite and includes two models: the pharmacological interaction (p–i) model and the altered peptide repertoire model (Pichler 2002). The p–i model proposes that a drug or its metabolite directly and non-covalently binds to the human leukocyte antigen (HLA) molecule on APC in a region exposed to T-cells. In this model, antigen processing (generation of drug-self peptide complex) in APC can be bypassed. For example, carbamazepine was shown to bind the HLA-B*15:02 protein and induce CTL-mediated keratinocyte lysis, supporting this model (Wei et al. 2012). The altered peptide repertoire model, although distinct from the p–i model, is closely related and therefore discussed along with the p–i model. It postulates that the drug strongly binds to the cleft of a HLA molecule and alters the repertoire of the self-peptides presented by the HLA protein to T-cells. The anti-HIV drug abacavir was suggested to bind strongly to its associated HLA-B*57:01 protein and change the bound self-peptide (Illing et al. 2012).
Activation of the immune system based on any of these three hypotheses involves the classical sensitization and elicitation mechanism by which drugs presented by APC sensitize T<sub>H</sub> cells first, and then CTL are activated to induce keratinocyte damage through recognition of HLA-class I–drug complex. However, recently, the heterologous immunity model was raised (White et al. 2015). This hypothesis proposes that virus-specific T-cells may cross-react with drug-bound peptide–HLA complexes to initiate the immune response. As intrinsic T-cells against viruses can react with the drug complex, the sensitization process may be skipped in this model. This may explain the occasional rapid onset of a rash on first exposure to a drug.

Other mechanistic hypotheses include mitochondrial injury, unfolded protein response, and the inflammogen hypotheses, which may or may not involve a reactive metabolite (Cho and Uetrecht 2017). These effects could directly cause idiosyncratic drug reactions (IDR) or lead to the production of various DAMP that promote an immune response.

Although the mechanistic progress has been striking in this area, several obstacles still exist for the prediction of skin toxicity/adverse reactions. First, knowledge of pathophysiological mechanisms is still scarce to explain the diverse types of adverse skin reactions. To solve this problem, greater mechanistic understanding is clearly necessary. Second, most adverse skin reactions are thought to be immune- or metabolism-mediated (at least partly), and thus, human-specific. Therefore, it is difficult to predict skin reactions using animal models, and thus proper in vitro or transgenic animal models are warranted based on mechanisms. Third, the predictability of the currently used LTT is insufficient to find a true causative drug. New diagnostic methods are warranted considering the mechanisms.

**Molecular interaction between drugs and HLA/TCR in SJS and TEN**

As HLA is the most polymorphic gene in the human genome, and has the ability to present antigens to activate T-cells, HLA has been proposed to be the risk factor of SCAR. The previous studies of Chung et al. (2004) and Hung et al. (2005) first discovered the strong HLA genetic predisposition to SCAR in Han Chinese, which included (1) HLA-B<sup>*15:02</sup> and carbamazepine-, or oxcarbazepine-induced SJS/TEN (Hung et al. 2004; Chen et al. 2017), (2) HLA-B<sup>*58:01</sup> and allopurinol-induced SCAR (Hung et al. 2005), and (3) HLA-A<sup>*31:01</sup> and carbamazepine-induced DRESS and maculopapular eruption (Tate et al. 2006). These genetic associations were validated in different populations around the world (Lonjou et al. 2008; Tassaneeyakul et al. 2009; McCormack et al. 2011; Genin et al. 2014). In addition, there are increasing reports showing that drug hypersensitivity has strong HLA genetic predisposition, for example, abacavir hypersensitivity and HLA-B<sup>*57:01</sup> (Mallal et al. 2002), and dapsone hypersensitivity and HLA-B<sup>*13:01</sup>. (Zhang et al. 2013). Table 1 shows examples of HLA types reported to be associated with specific drug-induced SCARs in the ethnic populations (Kaniwa and Saito 2013; Chung et al. 2016). Based on these scientific reports, HLA markers are described in drug labels in several countries. Table 2 displays a description of HLA marker types in carbamazepine labels.

In addition to the immune determinant HLA genes, cytochrome P 2C9 (CYP2C9) variants causing defects of drug metabolism were shown to be strongly associated with phenytoin-induced SCAR (Chung and Hung 2014). The defects of drug metabolism or clearance could also be due to renal deficiency and underlying disease can lead to the accumulation of drug antigens (Chung and Hung 2014; Chung et al. 2015; Yang et al. 2015; Ng et al. 2016). The delayed drug clearance was associated with increased serum levels of granulysin, and high mortality within SCAR patients (Chung et al. 2015; Yang et al. 2015; Ng et al. 2016). As the strength of association is strong, numerous genetic markers have been applied in clinics to prescreen patients and identify genes that may indicate a predisposition to SCAR (Mallal et al. 2008; Chen et al. 2011; Pan et al. 2017).

**Table 1.** Examples of associated HLA types with SCARs.

| Types       | Drugs                  | SCARs                              | Ethnicities                          |
|-------------|------------------------|------------------------------------|--------------------------------------|
| HLA-B<sup>*15:02</sup> | Carbamazepine          | SJS/TEN                            | Han Chinese, Thai, Malay, and Indian |
| HLA-B<sup>*15:11</sup>  | Carbamazepine          | SJS/TEN                            | Japanese, Korean, and Han Chinese    |
| HLA-A<sup>*31:01</sup> | Carbamazepine          | SJS/TEN/DRESS/ME                   | Han Chinese, Caucasian, Japanese, and Korean |
| HLA-B<sup>*58:01</sup> | Allopurinol            | SJS/TEN/HSS (inc. DIHS/DRESS)      | Han Chinese, Thai, Malay, Korean, Caucasian, and Japanese |
| HLA-B<sup>*57:01</sup> | Abacavir               | HSS                                | Caucasian, African, Thai, and Cambodian |
| HLA-A<sup>*02:06</sup> | Cold medicine          | SJS/TEN                            | Japanese and Korean                 |
| HLA-B<sup>*15:02</sup>C<sup>*08:01</sup> haplotype | Sulfamethoxazole/Trimethoprim | SJS/TEN                           | Thai                                   |
| HLA-B<sup>*35:05</sup> | Nevirapine             | Skin reaction                      | Thai                                  |
| HLA-B<sup>*59:01</sup> | Methazolamide          | SJS/TEN                            | Korean and Japanese                 |

HSS: Hypersensitivity syndrome. Compiled from (Kaniwa and Saito 2013; Ueta et al. 2014; Kongpan et al. 2015; Chung et al. 2016)

**Table 2.** Description of HLA marker types in carbamazepine labels.

| Drug          | HLA type | Country/<sup>a</sup> | HLA testing in the package insert |
|---------------|----------|-----------------------|----------------------------------|
| Carbamazepine | B<sup>*15:02</sup> | USA                   | Prior test should be performed in patients with ancestry in genetically at-risk populations (Asians) |
|               |          | Australia             | Prior test should be performed in patients with ancestry in genetically at-risk populations |
|               |          | Canada                | Test is recommended to be considered in patients with ancestry in Asian populations (reimbursed by health insurance) |
|               |          | Singapore             | Testing is highly recommended in patients with Asian ancestry |
|               |          | Japan                 | Reminded                          |
|               | A<sup>*31:01</sup> | Australia             | Prior test should be considered in patients with ancestry in genetically at-risk populations |
|               |          | Canada                | Test is recommended to be considered in genetically at-risk populations |
|               |          | USA                   | The risks and benefits of carbamazepine therapy should be weighed in patients known to be positive with this allele |
|               |          | Taiwan                | Presence of HLA-A<sup>*31:01</sup> should be considered prior to initiation of treatment |
|               |          | Japan                 | Reminded                          |

<sup>a</sup>https://www.accessdata.fda.gov/drugsatfda, https://www.ebs.tga.gov.au, https://www.fda.gov.tw, https://pdf.hres.ca, https://eservice.hsa.gov.sg, http://www.pmda.go.jp
The HLA and CYP predisposition observed in drug hypersensitivity are not only genetic markers, but play immunotoxicologic functional roles in the pathogenesis of SCAR. By applying mass spectrometry, Yang et al. (2007) reported that there was no detection of specific carbamazepine-modified peptides with HLA-B*1502 protein. Wei et al. (2012) reported that endogenous peptide-loaded HLA-B*15:02 molecules presented carbamazepine to CTL without involvement of intracellular drug metabolism or antigen processing. The HLA-B*15:02-peptide-β₂-microglobulin protein complex exhibited binding affinity toward chemicals with 5-carboxa-mide on the tricyclic ring, such as carbamazepine and oxcarbazepine. HLA-B75 family members share a structure similar to that of HLA-B*15:02, and could also present carbamazepine to activate CTL cells. Three residues (Asn63, Ile95, and Leu156) in the peptide-binding groove of HLA-B*15:02 were involved in carbamazepine presentation and CTL activation. In particular, Asn63 shared by members of the B75 family was seen to be the key residue. Computer simulations revealed a preferred molecular conformation of the 5-carboxamide group of carbamazepine and the sidechain of Arg62 on the B pocket of HLA-B*15:02. Furthermore, prefer-ential T-cell receptor (TCR)-Vβ and TCR-Vα usages and oligo-clonal expansion of TCR were identified in the ex vivo drug-expanded cultures of peripheral blood mononuclear cells (PBMC) of patients with carbamazepine-induced SJS/TEN (Ko et al. 2011). That study showed that the expression of TCR was drug-specific and phenotype-specific, and that TCR transfectants showed an immune response to the drug in a HLA-restricted manner.

Binding of the allopurinol metabolite, oxypurinol, to HLA-B*58:01 molecule was also identified by T-cell proliferation assays and in silico analysis (Lin et al. 2015). A high concentration of oxypurinol stimulated the T-cells of PBMC of patients with allopurinol-SCAR to produce granulysin and granzyme B (Chung et al. 2015). The Arg97 located between the E and C pocket of HLA-B*58:01 was identified as a key residue for oxypurinol binding (Lin et al. 2015). Furthermore, the technology of next-generation sequencing was applied to study TCR clonotypes of allopurinol-induced SCAR (Chung et al. 2015). Preferential TCR-V-β usage and clonal expansion of specific CDR3 (third complementarity-determining region) were identified in blister cells from skin lesions and oxypurinol-activated T-cells from allopurinol-SCAR patients (Chung et al. 2015).

In summary, these molecular and functional studies on carbamazepine and allopurinol revealed that in susceptible subjects, the plasma levels of drug antigens increased due to the defects of drug metabolism, and the genetically associated HLA-B molecules have the ability to present drug antigens to clonotype-specific T-cells, supporting the p-i model. On recognizing the drug antigen-HLA protein complex, T-cells express cytotoxic proteins (e.g. granulysin) and cytokines (e.g. IL-15), resulting in extensive skin lesions in SCAR. As viral reactivation was found in the acute stage of DRESS patients and several viral infections share the clinical presentation of SJS/TEN (Chiou et al. 2008; Chung et al. 2013), previous immune history or microbial infections may contribute to the diversity of the TCR repertoire (White et al. 2015). Further studies are needed to investigate the immunological basis of different types of drug hypersensitivity.

**The innate immune response: inflammasome activation in the skin**

An important question in understanding the etiology of drug-induced skin reactions is how APC are activated in the skin. Contact hypersensitivity is similar to drug-induced skin rashes in that in both cases many, if not most, appear to involve chemically reactive species. It was found that mice that lack components of the inflammasome are resistant to contact hypersensitivity (Watanabe et al. 2007). Inflammasomes are multimeric protein complexes that are involved in producing an inflammatory response to pathogen-associated molecular pattern (PAMP) and DAMP molecules. They convert procaspase-1 to active caspase-1 that, in turn, converts pro-IL-1β, and pro-IL-18 into their active forms (Man and Kanneganti 2015). The most studied inflammasome is NLRP3. Inflammasome activation has been implicated in many chronic diseases including multiple sclerosis, Alzheimer’s disease, atherosclerosis, and Type 2 diabetes (Guo et al. 2015).

The ability of a drug to activate inflammasomes in macrophages appears to predict whether it can cause skin rashes or not (Weston and Uetrecht 2014). However, the drugs tested had intrinsic chemical reactivity and could directly activate macrophages. Many drugs presumably require metabolic activation, and most drug-metabolizing enzymes in the skin appear to reside in keratinocytes. Therefore, in most cases, it may be that various DAMP produced by keratinocytes lead to the activation of inflammasomes in APC and other macrophages. This, in turn, could lead to an immune-mediated skin rash in susceptible patients.

**Reactive metabolite formation in the skin**

Circumstantial evidence suggests that many IDR are due to reactive metabolites or chemically reactive drugs, such as the β-lactams. Reactive metabolites can be formed by almost any metabolic pathway including oxidation, reduction, acetylation, sulfa- tion, and glucuronida-tion. The metabolic enzymes with the greatest activity in the skin lead to sulfation and acetylation (Baron and Merk 2001). Although it is possible that reactive metabolites formed in the liver or elsewhere could cause an immune response in the skin, given the short half-life of most reactive metabolites, it seems most likely that for a reactive metabolite to cause a skin rash it must be formed in the skin. For example, the reactive benzylic sulfate of nevirapine is also formed in the liver and could be detected in the serum of treated rats. However, inhibition of sulfation in the liver did not prevent the skin rash while a topical sulfotransferase inhibitor did prevent it (Sharma et al. 2013).

Most reactive metabolites are formed by oxidation, and the major enzymes involved in the oxidation of drugs to reactive metabolites are the cytochromes P₄₅₀ (CYPs). CYP1A1, 1B1, and 2E1 have been identified in Langerhans cells differentiated from CD34⁺ cells, adult normal keratinocytes, fibroblasts and melanocytes, and CYP2C, 2D6, and 3A5 were identified in fibro-blasts (Saeki et al. 2002). These results were replicated by a microarray analysis, in which the CYP1A1, 1B1, and 2E1 were expressed at comparable levels with the liver (Baron et al. 2008). Additionally, several other drug-metabolizing enzymes including sulfo transferases, N-acetyl-transferases, UDP-glucuronosyltransferases, flavin mono-oxygenase (FMO), and carbonyl-esterases are reported to be expressed in the skin (Hu et al. 2010). For further extensive discussion on this subject, please see the review by Sharma et al. (2013).

Although mRNA coding for various P₄₅₀ are found in the skin, the expression of these proteins in the skin is low, and there are very few examples in which drugs have been shown to be oxidized to reactive metabolites in the skin. Furthermore,
most drugs that form P_{450}-mediated reactive metabolites and cause idiosyncratic liver injury are not associated with a significant risk of skin rash though it is much easier to induce an immune response in the skin than in the liver.

Many drugs associated with IDRs have the potential to form several reactive metabolites. For example, the skin rash due to nevirapine is clearly caused by a reactive benzylic sulfate formed in the skin while most of the covalent binding in the liver involves the formation of a reactive quinone methide mediated by P_{450}. Carbamazepine forms a 10,11-epoxide, which is weakly reactive (Yip et al. 2017). Its phenolic metabolites suggest that it can also form a 2,3 epoxide. 2-hydroxy carbamazepine can be further oxidized to an iminoquinone (Ju and Uetrecht 1999), 3-hydroxy carbamazepine can be oxidized to a relatively stable free radical (Lu and Uetrecht 2008), and the glycol metabolite formed by hydrolysis of the 10,11-epoxide has the potential to form a benzylic sulfate analogous to that of nevirapine. These pathways are shown in Figure 1. At present, it is unknown which, if any, of these potential reactive metabolites is responsible for the IDRs associated with carbamazepine, which includes TEN. The observation that polymorphisms in epoxide hydrolase are not associated with an altered risk in developing carbamazepine-induced hypersensitivity reactions (including TEN) suggests, but does not prove, that an epoxide is not responsible for the IDRs associated with this drug (Green et al. 1995). In addition, although the 10,11-epoxide has a long half-life and can reach the skin, oxcarbazepine also causes TEN. The same HLA gene is a risk factor; however, oxcarbazepine cannot form a 10,11-epoxide. The 10,11-epoxide is hydrolyzed to a diol and this could form a sulfate conjugate, which is a benzylic sulfate analogous to the sulfate of 12-hydroxy nevirapine and predicted to be reactive. Carbamazepine is believed to form a 2,3-epoxide based on the observed 2-, and 3-hydroxy carbamazepine metabolites. However, this epoxide has not been detected in serum and is unlikely to reach the skin in significant concentrations. The 2,3-epoxide could be formed in the skin, but the cytochrome P_{450} levels in skin are low. The 2-hydroxy carbamazepine can be further oxidized to a reactive iminoquinone. Carbamazepine can also cause agranulocytosis and aplastic anemia. It is oxidized to an acridine derivative by myeloperoxidase, and this involves a ring contraction that presumably goes through a reactive carbocation intermediate. Thus there are many candidates for the chemical species that is responsible for serious carbamazepine-induced skin rashes, and it may be a combination of metabolites or it is also possible that carbamazepine itself could be responsible for causing skin rashes. (Adapted from Ju and Uetrecht [1999], Lu et al. [2008], and Yip and Pirmohamed [2017]).
formed analogous to the bioactivation of nevirapine. The fact that drug, such as carbamazepine, often causes systemic hypersensitivity reactions suggesting that they also form reactive metabolites outside the skin. Without a valid animal model, it is very difficult to determine which chemical entity is responsible for carbamazepine-induced hyper-sensitivity reactions, and different species could be responsible for different IDRs, as appears to be the case for nevirapine.

Sulfation is an attractive metabolic pathway for the formation of reactive metabolites in the skin because, unlike with the various $P_{450}$ sulfortransferase activity is high in the skin. One of the few drugs that causes skin rashes and has been shown to be oxidized by these $P_{450}$ in the skin is lamotrigine (Chen et al. 2010). It forms a glutathione conjugate when incubated with keratinocytes, and the glutathione conjugate is presumably formed from an epoxide. However, the reaction constant $K_m$ is very high, and the glutathione conjugate was not detectable unless very high concentrations of lamotrigine were used. Another metabolite of lamotrigine is the $N$-oxide. $N$-Oxides, such as minoxidil, are substrates for sulfortransferase. The sulfate of lamotrigine $N$-oxide is reactive (Lu and Uetrecht 2007), and preliminary evidence suggests that it is formed by human sulfortransferases (unpublished observation). Presumably IDRs caused by lamotrigine could be due to the parent drug through the $p-i$ mechanism. Without a valid animal model, it will be very difficult to test these various hypotheses. A similar problem may exist for other drugs that have the potential to form reactive sulfate conjugates.

If, as discussed below, the dominant immune response to drugs that can cause IDRs is immune tolerance, blocking immune tolerance may unmask the ability of a drug to cause skin rashes. A major molecule involved in immune tolerance is the checkpoint molecule PD-1. Therefore, it may be possible to develop an animal model using the PD-1$^{-/-}$ mouse; however, the benzylic alcohol of nevirapine is not a substrate for murine sulfortransferases, and nevirapine does not induce a skin rash in mice.

**Animal models of hypersensitivity reactions**

**Nevirapine-induced skin rash model**

Nevirapine causes skin rash in about 10% of patients treated with drug; however, in early clinical trials almost everyone developed a rash when the dose was escalated (Uetrecht; personal communication). In most patients, the rash is mild; unfortunately, severe rashes such as TEN can occur. Nevirapine also caused a skin rash in rats; an accidental finding while trying to identify potential reactive metabolites of nevirapine (Uetrecht, personal communication). The rash was idiosyncratic in that it did not occur in male rats, the incidence was about 20% in female Sprague Dawley rats, but it was 100% in female Brown Norway rats (Shenton et al. 2003). The rash was clearly immune mediated as it occurred more rapidly in rats that had been previously sensitized by treatment with nevirapine, and this sensitivity could be transferred to naïve rats with lymphocytes from sensitized rats. In addition, depletion of CD4 T-cells prevented rash (Shenton et al. 2005). The characteristics of rash in rats were similar to the rash in humans, especially in patients with low CD4 T-cell count and are at decreased risk, and incubation of PBMC from patients with a history of nevirapine-induced rash with nevirapine also resulted in the release of interferon (IFN)-$\gamma$ (Chen et al. 2009). Therefore, this appears to be a very good animal model of an IDR, and possibly the only animal model of an IDR with characteristics similar to that of the IDR in humans that occurs without manipulation of the immune system.

The nevirapine model also allowed for testing the basis for the $p-i$ hypothesis. Peripheral mononuclear leukocytes from animals that have had a nevirapine-induced skin rash were activated by the parent drug, despite the fact that it is the reactive benzyl sulfate that induces the rash (Chen et al. 2009). Therefore, what the lymphocytes from a patient who has had an IDR respond to in vitro is not necessarily what induced the IDR in the first place, which suggests that the basis for the $p-i$ hypothesis is false. Thus, although the in vitro results suggest that nevirapine-induced skin rash involves the $p-i$ hypothesis, the rash is due to reactive metabolite. That calls into question other in vitro studies that have been used to support the $p-i$ hypothesis; therefore, the $p-i$ hypothesis remains a hypothesis without definitive supportive evidence. These are two examples of the power of a valid animal model that made it possible to test hypotheses that would be virtually impossible to test in humans.

An important factor for developing animal models of IDRs is immune tolerance

Nevirapine is an exception; other attempts to reproduce adverse reactions in animals similar to IDRs in humans have failed. In addition, even though nevirapine can also cause idiosyncratic liver injury in humans, and Brown Norway rats develop a skin rash similar to the rash that it causes in humans, the rats did not develop liver injury. Extensive efforts to develop animal models based on the current hapten and danger hypotheses have been unsuccessful. Based on the danger hypothesis, and in addition to treating animals with drugs that cause IDRs in humans and covalently bind to hepatic proteins, the Uetrecht laboratory tried to activate APC through toll-like receptors, for example, lipopolysaccharide (LPS) and polyinosinic-polycytidylic acid (poly-IC). This was done with several drugs, but without success; most of this work was never published. This is consistent with the clinical observation that patients with inflammatory conditions such as ulcerative colitis do not appear to have a higher risk of IDR. In most cases, the immune system seems to be able to determine whether the danger signal came from the drug or some other factor, and only respond to the drug if it is the drug that caused the injury. Immunizing animals with isoniazid- or amodiaquine-modified hepatic proteins followed by treatment with the drug, only led to immune tolerance (Mak and Uetrecht 2015b). This is consistent with the fact that patients with mild IDRs often have resolution of the IDR despite continued treatment with the drug. If the injury is immune mediated, then the resolution of the mild injury must involve immune tolerance. Therefore, if it is immune tolerance that keeps most animals and humans from having an IDR to a drug that commonly causes IDR, it might be possible to develop an animal model by inhibiting immune tolerance. In fact, this strategy works. Specifically, immune checkpoint inhibition using a combination of PD-1$^{-/-}$ mice and anti-CTLA-4 antibodies unmasks the potential of drugs to cause idiosyncratic drug-induced liver injury (Mak and Uetrecht 2015a; Metushi et al. 2015), and therefore has the potential to test hypotheses that have not been possible to test in the past.

**In vitro strategies to study immunological drug reactions**

Susceptibility to drug hypersensitivity is a function of the chemistry of the drug, the genetics of the patient, and environmental
factors the patient was exposed to at the time of reaction. It is incredibly difficult to apply each of these factors to an in vitro cell system; as such there are no currently no assays available for predicting drug immunogenicity. The purpose of this section of the article is to provide a brief summary of what is known about drug-specific T-cell responses and how this knowledge is being used to develop novel T-cell priming assays that may in the future be used to screen for drug immunogenicity and skin sensitization.

Whenever possible T-cells isolated from blood and tissues of hypersensitive patients should be used to investigate the cellular pathophysiology of the adverse event and the way in which drugs interact with immune receptors (major histocompatibility complex [MHC] and the T-cell receptor [TCR]), as with these cells one can reimagine in vitro the relevant drug immune cell interactions. As discussed earlier, the discovery of strong associations between expression of single HLA alleles and susceptibility to drug hypersensitivity has changed the way in which we view hypersensitivity reactions to drugs; they are no longer totally unpredictable. As such, it is important that all mechanistic studies use cells from HLA-typed patients alongside a battery of in vitro assays to characterize the effects of drug treatment on DC signaling and the activation of cells of the adaptive immune system. Moreover, state-of-the-art mass spectrometers should be available to study the metabolism of drugs in in vitro culture systems, characterize and quantify the binding of drug metabolites to protein, and relate the chemistry of adduct formation to the biological response (i.e. activation of T-cells). Figure 2 illustrates a research strategy that could be applied to study drug hypersensitivity using patient cells.

**Activation of hypersensitive patient T-cells with drugs**

Several drugs are directly protein-reactive, while others gain protein reactivity through drug metabolism. Reactive drugs bind covalently to nucleophilic amino acid residues on proteins to form adducts that, following protein processing, yields MHC binding peptides that activate T-cells (Meng et al. 2017). APC express low levels of drug metabolizing enzymes, when compared with hepatocytes; however, the levels of adducts formed from some drugs have been shown to be sufficient to bind to protein and form adducts that activate T-cells (Elsheikh et al. 2011). Reactive drug metabolites in in vitro culture also bind directly to MHC bound peptides to activate T-cells (Schnyder et al. 2000; Castrejon et al. 2010). Whether this represents an in vitro artifact mimicking a naturally processed protein adduct is currently not known. Drugs can also interact with MHC and T-cell receptors directly.

Classical studies demonstrated that T-cell receptors can be triggered with drugs rapidly (within minutes) through a pathway that does not require protein processing (Schnyder et al. 1997; Zanni et al. 1998). Abacavir has been shown to bind deep within the MHC peptide binding cleft, altering the space available for peptides to bind (Illing et al. 2012; Norcross et al. 2012; Ostrov et al. 2012). As such, a novel repertoire of peptides interact with the abacavir-modified MHC molecules, and it is believed that
T-cells responsible for abacavir hypersensitivity are triggered by these peptide sequences. For all other drugs shown to activate T-cells directly (e.g. sulfa-methoxazole [Schnyder et al. 1997], oxy-purinol [Yun et al. 2013], lamotrigine [Naisbitt et al. 2003]), the nature of the MHC binding interaction has not been defined.

**Development of assays to study the priming of naïve T-cells**

Studies utilizing hypersensitive patient T-cells are important, but they tell nothing about the origin of the drug-specific T-cell response. For this reason, researchers at the Medical Research Council (MRC)-funded Liverpool Centre for Drug Safety Science have spent 5 year developing cellular platforms using PBMC from healthy drug-naïve volunteers to study T-cell priming. The following section details the evolution of such assays, their current application domain and how further development might result in in vitro test systems to predict the intrinsic immunogenicity of new compounds. The availability of such assays is important as hypersensitivity often fails to be detected until post-marketing. As such, hypersensitivity reactions are a leading cause for drug withdrawal, resulting in patients needing to wait until an alternative is brought to the market (Negrini and Becquemont 2017).

Newman et al. (1977) were the first to report that human lymphocytes could be primed in vitro against chemical sensitizers. Subsequently, Seldin and Rich (1978) devised an in vitro system to study both primary and secondary responses of lymphocytes to hapten-conjugated proteins. Co-culture of lymphocytes with hapten-modified PBMC resulted in antigen-specific proliferative responses. The method has been modified in several subsequent studies; specifically, different forms of DC have been used as APC with naïve T-cells as responders. This allowed for discrimination of strong sensitizers from irritants. However, weak sensitizers failed to activate T-cells. In recent years, improved protocols have been used to generate DC, and T-regulatory (T_{reg}) cells have been removed from responders to enhance sensitivity. Furthermore, multiple readouts are now available to detect the antigen-specific T-cell responses (Dietz et al. 2010; Martin et al. 2010).

Researchers at Liverpool developed methods to study the origin of drug- and drug metabolite-specific T-cell responses in healthy donors (Faulkner et al. 2012, 2016; Monshi et al. 2013). The assay relies on isolation and culture of autologous monocyte-derived DC and naïve T-cells as APC and responder cells, respectively. After a 7–10 d culture period, T-cells are re-exposed to the drug antigen and DC before antigen specificity is measured shortly after. In addition to classical readouts for proliferation, cytokine secretion and cytotoxicity, a change in phenotype from naïve T-cell to memory T-cell is quantified by flow cytometry. Strong responses are detected to haptenic drug metabolite(s), such as piperacillin and nitroso sulfamethoxazole (Faulkner et al. 2016). T-Cell priming is also detected against direct MHC binding drug metabolite(s), including sulfamethoxazole, carbamazepine, and oxy-purinol. The platform is flexible in that it can be used to study (1) the phenotype of activated T-cells, (2) HLA-allele-restricted forms of hypersensitivity, (3) immune regulation, and (4) tissue-specific signaling, as briefly discussed below.

**Immune cells activated by drugs**

Chemically distinct drugs and metabolites have been shown to prime naïve T-cells, produce polarized cytokine secretion profiles following re-stimulation and display selective chemokine migration properties (Faulkner et al. 2012, 2016). In contrast, abacavir preferentially activates pre-existing memory T-cells from healthy donors that must have been primed by earlier exposure to another foreign antigen (Lucas et al. 2015). Most recently, focusing on sulfamethox-azole, we have shown that naïve and memory T-cells from healthy donors can be stimulated by parent drug and drug metabolites (Gibson et al. 2017). These data highlight the need to study naïve and memory T-cell populations.

**HLA alleles**

Several strong associations between susceptibility to specific forms of immunological drug reaction and expression of HLA alleles have been identified. For certain drugs, it has been possible to relate the genetic association to the disease by showing that T-cells are selectively activated in individuals expressing the risk allele. To study the propensity of drugs to initiate T-cell responses, it is critical to work with genetically characterized cells. For this to be feasible, the Naisbitt laboratory has established a unique HLA genotyped cell bank containing ≈100 million PBMC from 1000 healthy donors.

**Immune regulation**

Most HLA associations with drug hypersensitivity have a low prognostic value (e.g. HLA-B*57:01 is associated with fluorociclin-induced liver injury, but only 1/1000 HLA-B*57:01-expressing individuals develop hypersensitivity). Therefore, additional immunological parameters are involved in regulating the activation of drug-specific T-cells. Co-stimulatory and co-inhibitory pathways signal simultaneously to regulate whether antigen exposure will lead to T-cell activation. Thus, it is conceivable that dysregulation of these pathways may manipulate the threshold of T-cell activation to such an extent that they enhance a patient’s susceptibility to drug hypersensitivity. Indeed, an inhibitory role for the PD-1 and CTLA-4 pathways during the priming of naïve T-cells to drugs has been reported (Gibson et al. 2014, 2017). As research moves forward, it will be crucial to elucidate the effect of modulation of multiple cosignaling pathways together to effectively analyze the role of inhibitory signaling during T-cell activation.

**Tissue microenvironment**

A limitation of existing T-cell priming assays is that immune cells are exposed to drugs directly or conjugated to a carrier protein. Assay development is complicated by the fact that many drugs are not directly protein-reactive, and as such, antigenic determinants are not always generated in the assay. Furthermore, the cross-talk between tissue and immune cells is important in determining the outcome of compound exposure. For example, hepatocytes treated with model hepatotoxins release signals that promote the secretion of polarizing cytokines from DC (Ogese et al. 2017). Thus, new strategies need to be developed to enhance exposure of immune cells to relevant tissue-specific stress signaling and tissue-derived drug-protein adducts. Development of a tissue/immune cell culture system has been a challenge for the investigation of drug immuno-genicity in humans as autologous cells are required. One way to overcome this shortcoming will be the generation of induced pluripotent stem cells (iPS)-derived keratinocyte lines and antigen-specific T-cells from the same donors expressing an important HLA risk allele.
Development of screening assays

Existing T-cell priming assays are still far from perfect. A major drawback is the experimental design, which is time-consuming and is more suited for laboratory-based investigation of a few variables. As such, they cannot currently be used to screen new compound for the potential to cause immune responses when administered to humans. A reason for this is the absence of medium/high throughput assays. Efforts to transform existing assays into suitable platforms for the screening of drugs are focused on miniaturization to assess (1) multiple HLA-typed individuals simultaneously and (2) multiple experiments with cells from one individual. The eventual transfer of such assays to industrial partners provides a pathway for assessment of immunogenicity of novel drugs and for initial application of the newly established methods.

Conclusions

Skin rashes continue to represent a significant clinical problem, and our mechanistic understanding is superficial. A simplified scheme of a reasonable hypothesis for the mechanism of serious skin rashes is shown in Figure 3. The components of this hypothesis should be tested, and the only practical way to do this is by developing valid animal models that replicate the metabolic pathways in humans to accurately predict which drug candidates are likely to pose a significant risk of serious skin rashes.

Disclosure statement

The authors alone are responsible for the content of this review.

ORCID

Jeanine Bussiere http://orcid.org/0000-0001-6439-4051

References

Adam J, Eriksson K, Schnyder B, Fontana S, Pichler W, Yerly D. 2012. Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur J Immunol. 42:1706–1716.

Baron J, Merk H. 2001. Drug metabolism in the skin. Curr Opin Allergy Clin Immunol. 1:287–291.

Baron J, Wiederholt T, Heise R, Merk H, Bickers D. 2008. Expression and function of cytochrome p450-dependent enzymes in human skin cells. Curr Med Chem. 15:2258–2264.

Calne R, Sells R, Pena J, Davis D, Millard P, Herbertson B, Binns R, Davies D. 1969. Induction of immunological tolerance by porcine liver allografts. Nature 223:472–476.

Castrojon I, Berry N, El-Ghaiesh S, Gerber B, Pichler W, Park B, Naisbitt D. 2010. Stimulation of human T-cells with sulfonamides and sulfonamide metabolites. J Allergy Clin Immunol. 125:411–418.

Chen C, Hsiao Y, Wu T, Hsih M, Tassaneeyakul W, Jorns T, Sukasem C, Chang W, et al. 2017. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology 88:78–86.

Chen H, Grover S, Yu L, Walker G, Mutlib A. 2010. Bioactivation of lamotrigine in vivo in rat and in vitro in human liver microsomes, hepatocytes, and epidermal keratinocytes: Characterization of thioether conjugates by liquid chromatography/mass spectrometry and high field nuclear magnetic resonance spectroscopy. Chem Res Toxicol. 23:159–170.

Figure 3. Hypothesis by which a drug can cause a serious drug rash. Keratinocytes can metabolize some drugs to reactive metabolites, especially through the formation of reactive sulfate conjugates. The reactive metabolites can both covalently bind to proteins and cause cell damage leading to the release of danger associated molecular pattern (DAMP) molecules. These DAMP can activate dermal DC through toll-like receptors (TLR) that, in turn, can activate inflammasomes. In addition, the DC also process drug-modified proteins leading to drug-modified peptides. When presented in the context of major histocompatibility complex-1 (MHC-1), these peptides can be recognized by T-cells with the appropriate T-cell receptor. This can lead to the production of CTL that kill keratinocytes that express the drug modified peptides. This is grossly oversimplified as many other cells, such as Tc cells, are also involved, many other molecules such as chemokines and cytokines are involved, and the initial activation of T-cells occurs in lymph nodes, not in the skin. There are also mechanisms that can lead to immune tolerance, such as activation of Treg cells that prevent serious skin rashes in most individuals.
Cho Y, Lin J, Chen Y, Chang C, Hsiao C, Chung W, Chu CY. 2014. Clausen B, Stoitzner P. 2015. Functional specialization of skin dendritic cell
Faulkner L, Gibson A, Sullivan A, Tailor A, Usui T, Alfirevic A, Boxer B, Park B, Naish AD. 2014. Regulation by PD-L1 during
drug-specific priming of IL-22-secreting T-cells and the influence of PD-1 on effector T-cell function. J Immunol. 192:2611–2621.
Green V, Pirmohamed M, Ritteringham N, Gaedigk A, Grant D, Boxer M, Burchell B, Park B. 1995. Genetic analysis of microsomal epoxide
hydrolase in patients with carbamazepine hypersensitivity. Biochem Pharmacol. 50:1333–1339.
Guo H, Callaway J, Ting J. 2015. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 21:677–687.
Hodi F, O’Day S, McDermott D, Weber R, Sosman J, Haanen J, Gonzalez R, Robert C, Schadenbord D, Hasel J, et al. 2010. Improved survival with
ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723.
Hu T, Khambatta Z, Hayden P, Bolmarcich J, Binder R, Robinson M, Carr G, Tiesman J, Jarroll B, Osborne R, et al. 2010. Xenobiotic metabolism
gene expression in the EpiDerm vitro 3D human epidermis model compared to human skin. Toxicol In Vitro 24:1450–1463.
Hung S, Chung W, Liou L, Chu C, Lin M, Huang L, Lin Y, Lan J, Yang L, Hong S, et al. 2005. HLA-B*5801 allele as a genetic marker for severe
Cutaneous adverse drug reactions caused by allopurinol. Proc Natl Acad Sci. USA 102:4134–4139.
Illing P, Vivian J, Dudek N, Kostenko L, Chen Z, Bharadwaj M, Miles J, Kjer-Nielsen L, Gras S, Williamson N, et al. 2012. Immune self-reactivity
triggered by drug-modified HLA-peptide repertoire. Nature 486:554–558.
Ju C, Uetrecht J. 1999. Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminooxi-
none intermediate. J Pharmacol Exp Ther. 288:51–56.
Kaniwa N, Saito Y. 2013. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury. J Human Genetics 58:317–326.
Ko T, Chung W, Wei C, Shih H, Chen J, Lin C, Chen Y, Hung S. 2011. Shared and restricted T-cell receptor use is crucial for carbamazepine-
Induced Stevens-Johnson syndrome. J Allergy Clin Immunol. 128:1266–1276.
Kongpan T, Mahasirimongkol S, Konyawong W, Chumworrathayi P, Wichukchinda N, Kidkeukarun R, Preechakul S, Khunarkornsiri U, Bamrungram W, et al. 2015. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharmacogenomics 25:402–411.
Kouki T, Sawai Y, Gardine C, Fisfalen M, Alegre M, DeGroot L. 2008. Coxsackievirus A6 new variant induced widespread mucocutaneous bullous reactions mim-
icking severe cutaneous adverse reactions. J Invest Dermat. 135:2237–2248.
Kuok T, Tasto Y, Gardine C, Fisfalen M, Alegre M, DeGroot L. 2008. Coxsackievirus A6 new variant induced widespread mucocutaneous bullous reactions mim-
icking severe cutaneous adverse reactions. J Invest Dermat. 135:2237–2248.
Lally A, Turner R. 2007. A survey of approach to wound healing by second-
ary intention among British Society for Dermatological Surgery members. Br J Dermatol. 156:575–576.
Lamoreux M, Sternbach M, Hsu W. 2006. Erythema multiforme. Am Fam Physician 74:1883–1888.
Landsteiner K, Jacobs J. 1935. Studies on the sensitization of animals with
ALM61/C3

Burchell B, Park B. 1995. Genetic analysis of microsomal epoxide
hydrolase in patients with carbamazepine hypersensitivity. Biochem Pharmacol. 50:1333–1339.
Carbamazepine-induced severe cutaneous adverse reactions: An inter-
molecular interaction. J Allergy Clin Immunol. 135:1063–1065.
Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Lamoreux M, Sternbach M, Hsu W. 2006. Erythema multiforme. Am Fam Physician 74:1883–1888.
Landsteiner K, Jacobs J. 1935. Studies on the sensitization of animals with
ALM61/C3

Burchell B, Park B. 1995. Genetic analysis of microsomal epoxide
hydrolase in patients with carbamazepine hypersensitivity. Biochem Pharmacol. 50:1333–1339.
Mak A, Uetrecht J. 2015a. The combination of anti-CTLA-4 and PD1 blockade in mice unmasks the potential of isoniazid and nevirapine to cause liver injury. Chem Res Toxicol. 28:2287–2291.

Mak A, Uetrecht J. 2015b. Immunization with amodiaquine-modified hepatic proteins prevents amodiaquine-induced liver injury. J Immunotoxicol. 12:361–367.

Malall S, Nolan D, Witt C, Masel G, Martin A, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, et al. 2002. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727–732.

Malall S, Phillips E, Carosi G, Molina J, Workman C, Tomazic J, Jagel-Guedes E, Rugina S, Kozyev O, Cid J, et al. 2008. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568–579.

Man S, Kanneganti T. 2015. Regulation of inflammasome activation. Immunol Rev. 265:6–21.

Martin S, Esser P, Schmucker S, Dietz L, Naisbitt D, Park B, Voscanson M, Nicolas J, Kellner M, Pichler W, et al. 2010. T-Cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays. Cell Mol Life Sci. 67:4171–4184.

Matzinger P. 1998. An innate sense of danger. Semin Immunol. 10:399–415.

McCormack M, Alfrevic A, Bourgeois S, Farrell JJ, Kaspersiviütie D, Carrington M, Sills GJ, Marson T, Jia X, de Bakker PIW, et al. 2011. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 364:1134–1143.

Meng X, Zeng Y, Zhang L, Zhang J, Farrell J, Earnshaw C, Whitaker P, Peckham D, French N, Naisbitt D, Park B. 2017. Definition of the nature and haplotype of the β-lactam antigen required for t-cell activation in vitro and in patients. J Immunol. 198:4217–4227.

Metushi I, Hayes M, Uetrecht J. 2015. Treatment of PD-1(−) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology. 61:1332–1342.

Monshi M, Faulkner L, Gibson A, Jenkins R, Farrell J, Earnshaw C, Alfrevic A, Cederbrant K, Daly A, French N, et al. 2013. Human leukocyte antigen (HLA)-B*57:01-restricted activa-tion of drug-specific T-cells provides the immunological basis for fluocinolclin-induced liver injury. Hepatology 57:727–739.

Naisbitt D, Farrell J, Wong G, Depta J, Dodd C, Hopkins J, Gibney C, Chadwick D, Pichler W, Pirmohamed M, et al. 2003. Characterization of drug-specific T-cells from patients with lamotrigine hypersensitivity. J Allergy Clin Immunol. 111:1393–1403.

Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, Bagot M, Roujeau J. 2004. Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T-cells. J Allergy Clin Immunol. 114:1209–1215.

Negrini S, Becquemont L. 2017. HLA-associated drug hypersensitivity and the prediction of adverse drug reactions. Pharmacogenomics J 18:441–457.

Newman W, Stoner G, Bloom B. 1977. Primary in vitro sensitisation of human t-cells. Nature 269:151–153.

Ng C, Yeh W, Stoner C, Hung S, Yang C, Chang Y, Chang W, Lin Y, Chang C, Su S, et al. 2016. Impact of the HLA-B*57:08 allele and renal impairment on allopurinol-induced cutaneous adverse reactions. J Invest Dermatol. 136:1373–1381.

Norcross M, Luo S, Lu L, Boyne M, Gomarteli M, Rennels A, Woodcock J, Margulies D, McMurry C, Vernon S, et al. 2012. Abacavir induces loading of novel self-peptides into HLA-B*57:01: An autoimmune model for HLA-associated drug hypersensitivity. AIDS 26:F21–F29.

Oguse M, Ahmed S, Alferic A, Betts C, Dickinson A, Faulkner L, French N, Gibson A, Hirschfield G, Kammuller M, et al. 2017. New approaches to investigate drug-induced hypersensitivity. Chem Res Toxicol. 30:239–259.

Ostrov Y, Pharmaco Y, Sidney S, Harndahl M, Southwood S, Oseroff C, Lu S, Jakoncic J, de Oliveira C, et al. 2012. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA. 109:9959–9964.

Pan R, Rao D, Hung S, Chung W. 2017. Pharmacogenomic advances in the prediction and prevention of cutaneous idiosyncratic drug reactions. Clin Pharmacol Ther. 102:86–97.

Pichler W. 2002. Pharmacological interaction of drugs with antigen-specific immune receptors: The p-i concept. Curr Opin Allergy Clin Immunol. 2:301–305.

Pichler W. 2003. Delayed drug hypersensitivity reactions. Ann Intern Med. 139:683–693.

Pichler W, Tilch J. 2004. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 59:809–820.

Saecki M, Tshibina R, Ozawa S, Sawada J. 2002. mRNA expression of multiple cytotoxic P150 isozymes in four types of cultured skin cells. Int Arch Allergy Immunol. 127:333–336.
Yip V, Meng X, Maggs J, Jenkins R, Marlot P, Marson A, Park B, Pirmohamed M. 2017. Mass spectrometric characterization of circulating covalent protein adducts derived from epoxide metabolites of carbamazepine in patients. Chem Res Toxicol. 30:1419–1435.

Yun J, Mattsson J, Schnyder K, Fontana S, Largiader C, Pichler W, Yerly D. 2013. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T-cell response. Clin Exp Allergy. 43:1246–1255.

Zanni M, von Greyerz S, Schnyder B, Brander K, Frutig K, Hari Y, Valitutti S, Pichler W. 1998. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human αβ T lymphocytes. J Clin Invest. 102:1591–1598.

Zhang F, Liu H, Irwanto A, Fu X, Li Y, Yu G, Yu Y, Chen M, Low H, Li J, et al. 2013. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med. 369:1620–1628.